Skip to main content
Rapport Therapeutics, Inc. logo

Rapport Therapeutics, Inc. — Investor Relations & Filings

Ticker · RAPP ISIN · US75383L1026 US Manufacturing
Open in API
Filings indexed 168 across all filing types
Latest filing 2026-05-07 Interim / Quarterly Rep…
Country US United States of America
Listing US RAPP

About Rapport Therapeutics, Inc.

https://www.rapportrx.com/

Rapport Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing transformational small molecule medicines for patients with central nervous system (CNS) disorders. The company employs a precision medicine approach, focusing on neuroanatomically precise targeting to create therapies with the potential for powerful efficacy and fewer side effects. Its pipeline is centered on advancing new medications for a range of neurological conditions.

Recent filings

Filing Released Lang Actions
10-Q - Rapport Therapeutics, Inc. (0002012593) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)
Earnings Release Classification · 90% confidence The document is a Form 8-K ‘Current Report’ filed under Item 2.02 “Results of Operations and Financial Condition,” furnishing a press release with quarterly financial results and business highlights for the quarter ended March 31, 2026. This matches the definition of an Earnings Release (initial announcement of quarterly financial results). Q1 2026
2026-05-07 English
ARS - Rapport Therapeutics, Inc. (0002012593) (Filer)
Annual Report
2026-04-23 English
DEF 14A - Rapport Therapeutics, Inc. (0002012593) (Filer)
Proxy Solicitation & Information Statement
2026-04-23 English
8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce material events or corporate updates between periodic filings. The text includes a detailed disclosure of clinical trial results and a corporate presentation update, but it is not a full financial report like an Annual Report (10-K) or Interim Report (IR). It also does not fit categories like Earnings Release (ER) or Management Reports (MDA) because it focuses on clinical trial results and corporate presentation updates rather than financial results or management discussion. The document is not a proxy, voting result, or governance change. The presence of a corporate presentation and press release attached as exhibits aligns with typical 8-K disclosures. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other specific categories. The document length and content confirm it is a substantive filing, not just a brief announcement, so RNS is appropriate rather than RPA.
2026-04-21 English
144 - Rapport Therapeutics, Inc. (0002012593) (Subject)
Regulatory Filings
2026-03-30 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.